Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016)
Gilead Sciences (GILD) recorded Current Deferred Revenue of $202 million in Q4 2016, down 54.1% from $440 million a year earlier and down 44.0% from the prior quarter.
Powered by 
Analysis
Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016) Analysis & Trends
Starting with Q2 2009, Gilead Sciences' Current Deferred Revenue history includes 30 quarters.
- Annual Current Deferred Revenue has a five-year compound annual growth rate of 22.0% (FY2011 to FY2016).
- Across earlier years, Current Deferred Revenue came in at $440 million in FY2015 (+228.4%), $134 million in FY2014 (+20.7%), $111 million in FY2013 (+7.6%) and $103.16 million in FY2012 (+38.2%).
- The Q4 2016 figure is the lowest quarterly Current Deferred Revenue since Q1 2015.
- On a year-over-year basis, Current Deferred Revenue rose in six of the last eight quarters, with growth averaging 111.7%.
- Peak year-over-year performance for Current Deferred Revenue in the last five years was growth of 296.7% in Q2 2015, against a decline of 54.1% in Q4 2016 at the low end.
- Per Business Quant, the preceding three quarters came in at $361 million (Q3 2016), $345 million (Q2 2016) and $529 million (Q1 2016).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn |
| 10 | Vertex Pharmaceuticals | 135.25 Bn | 107.26 Bn | 2.84 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 202.00 Mn |
| Sep 30, 2016 | 361.00 Mn |
| Jun 30, 2016 | 345.00 Mn |
| Mar 31, 2016 | 529.00 Mn |
| Dec 31, 2015 | 440.00 Mn |
| Sep 30, 2015 | 356.00 Mn |
| Jun 30, 2015 | 501.00 Mn |
| Mar 31, 2015 | 191.00 Mn |
| Dec 31, 2014 | 134.00 Mn |
| Sep 30, 2014 | 116.88 Mn |
| Jun 30, 2014 | 126.28 Mn |
| Mar 31, 2014 | 111.79 Mn |
| Dec 31, 2013 | 111.00 Mn |
| Sep 30, 2013 | 127.28 Mn |
| Jun 30, 2013 | 112.12 Mn |
| Mar 31, 2013 | 124.37 Mn |
| Dec 31, 2012 | 103.16 Mn |
| Sep 30, 2012 | 99.05 Mn |
| Jun 30, 2012 | 93.66 Mn |
| Mar 31, 2012 | 100.19 Mn |
API Access
Gilead Sciences Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=GILD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();